Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05582707Phase 2Terminated

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

Role: collaborator

NCT05756985Recruiting

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Role: collaborator

NCT03865979Not ApplicableCompleted

AI ENRICH - AI Detection of ICH

Role: collaborator

NCT02880878Not ApplicableCompleted

ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)

Role: lead

All 4 trials loaded